RATIONALE: Unrecognized airway infection and inflammation in young children with cystic fibrosis (CF) may lead to irreversible lung disease; therefore early detection and treatment is highly desirable. OBJECTIVES: To determine whether the lung clearance index (LCI) is a sensitive and repeatable noninvasive measure of airway infection and inflammation in newborn-screened children with CF. METHODS: Forty-seven well children with CF (mean age, 1.55 yr) and 25 healthy children (mean age, 1.26 yr) underwent multiple-breath washout testing. LCI within and between-test variability was assessed. Children with CF also had surveillance bronchoalveolar lavage performed. MEASUREMENTS AND MAIN RESULTS: The mean (SD) LCI in healthy children was 6.45 (0.49). The LCI was higher in children with CF (7.21 [0.81]; P < 0.001). The upper limit of normal for the LCI was 7.41. Fifteen (32%) children with CF had an elevated LCI. LCI measurements were repeatable and reproducible. Airway infection was present in 17 (36%) children with CF, including 7 (15%) with Pseudomonas aeruginosa. Polymicrobial growth was associated with worse inflammation. The LCI was higher in children with Pseudomonas (7.92 [1.16]) than in children without Pseudomonas (7.02 [0.56]) (P = 0.038). The LCI correlated with bronchoalveolar lavage IL-8 (R(2) = 0.20, P = 0.004) and neutrophil count (R(2) = 0.21, P = 0.001). An LCI below the upper limit of normality had a high negative predictive value (93%) in excluding Pseudomonas. CONCLUSIONS: The LCI is elevated early in CF, especially in the presence of Pseudomonas and airway inflammation. The LCI is a feasible, repeatable, and sensitive noninvasive marker of lung disease in young children with CF.
RATIONALE: Unrecognized airway infection and inflammation in young children with cystic fibrosis (CF) may lead to irreversible lung disease; therefore early detection and treatment is highly desirable. OBJECTIVES: To determine whether the lung clearance index (LCI) is a sensitive and repeatable noninvasive measure of airway infection and inflammation in newborn-screened children with CF. METHODS: Forty-seven well children with CF (mean age, 1.55 yr) and 25 healthy children (mean age, 1.26 yr) underwent multiple-breath washout testing. LCI within and between-test variability was assessed. Children with CF also had surveillance bronchoalveolar lavage performed. MEASUREMENTS AND MAIN RESULTS: The mean (SD) LCI in healthy children was 6.45 (0.49). The LCI was higher in children with CF (7.21 [0.81]; P < 0.001). The upper limit of normal for the LCI was 7.41. Fifteen (32%) children with CF had an elevated LCI. LCI measurements were repeatable and reproducible. Airway infection was present in 17 (36%) children with CF, including 7 (15%) with Pseudomonas aeruginosa. Polymicrobial growth was associated with worse inflammation. The LCI was higher in children with Pseudomonas (7.92 [1.16]) than in children without Pseudomonas (7.02 [0.56]) (P = 0.038). The LCI correlated with bronchoalveolar lavage IL-8 (R(2) = 0.20, P = 0.004) and neutrophil count (R(2) = 0.21, P = 0.001). An LCI below the upper limit of normality had a high negative predictive value (93%) in excluding Pseudomonas. CONCLUSIONS: The LCI is elevated early in CF, especially in the presence of Pseudomonas and airway inflammation. The LCI is a feasible, repeatable, and sensitive noninvasive marker of lung disease in young children with CF.
Authors: Shannon B Donnola; Elliott C Dasenbrook; David Weaver; Lan Lu; Karishma Gupta; Anjali Prabhakaran; Xin Yu; James F Chmiel; Kimberly McBennett; Michael W Konstan; Mitchell L Drumm; Chris A Flask Journal: J Cyst Fibros Date: 2015-12-22 Impact factor: 5.482
Authors: Padmaja Subbarao; Carlos Milla; Paul Aurora; Jane C Davies; Stephanie D Davis; Graham L Hall; Sonya Heltshe; Philipp Latzin; Anders Lindblad; Jessica E Pittman; Paul D Robinson; Margaret Rosenfeld; Florian Singer; Tim D Starner; Felix Ratjen; Wayne Morgan Journal: Ann Am Thorac Soc Date: 2015-06
Authors: Sarath C Ranganathan; Graham L Hall; Peter D Sly; Stephen M Stick; Tonia A Douglas Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Simon Y Graeber; Zhe Zhou-Suckow; Jolanthe Schatterny; Stephanie Hirtz; Richard C Boucher; Marcus A Mall Journal: Am J Respir Cell Mol Biol Date: 2013-09 Impact factor: 6.914
Authors: Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall Journal: Expert Rev Respir Med Date: 2013-06 Impact factor: 3.772
Authors: Margaret Rosenfeld; Philip M Farrell; Margaret Kloster; Jonathan O Swanson; Thuy Vu; Lyndia Brumback; James D Acton; Robert G Castile; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Gwendolyn S Kerby; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie D Davis Journal: Eur Respir J Date: 2013-05-30 Impact factor: 16.671